FMP

FMP

Enter

AORT - Artivion, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/AORT.png

Artivion, Inc.

AORT

NYSE

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

24.12 USD

0.7 (2.9%)

Historical Prices

From:

To:

22.7622.823.123.423.72424.1809:30 AM09:49 AM10:09 AM10:29 AM10:48 AM11:08 AM11:27 AM11:47 AM12:06 PM12:28 PM12:47 PM01:06 PM01:25 PM01:44 PM02:03 PM02:24 PM02:43 PM03:02 PM03:21 PM03:40 PM03:59 PM

About

ceo

Mr. James Patrick Mackin

sector

Healthcare

industry

Medical - Devices

exchange

NYSE

Description

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system fo...

CIK

0000784199

ISIN

US2289031005

CUSIP

228903100

Address

1655 Roberts Boulevard N.W.

Phone

770 419 3355

Country

US

Employee

1,600

IPO Date

Feb 12, 1993

Financial Statement

-20M020M40M60M80M100M2023 Q42024 Q12024 Q22024 Q32024 Q4RevenueNet Income

Earnings

-0.5-0.4-0.3-0.2-0.100.10.22023 Q12023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q4EPS Consensus

AORT Financial Summary

CIK

0000784199

Exchange

NYSE

Industry

Medical - Devices

Sector

Healthcare

CUSIP

228903100

ISIN

US2289031005

Country

US

Price

24.12

Beta

1.79

Volume Avg.

406.63k

Market Cap

1.01B

Shares

-

52-Week

19.36-32.33

DCF

0.98

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-75.37

P/B

-

Website

https://artivion.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest AORT News

Andrew Wynn

Feb 25, 2025

Artivion, Inc. (NYSE: AORT) Earnings Report Analysis

Artivion, Inc. (NYSE: AORT) is a key player in the cardiac and vascular surgery industry. The company focuses on developing and manufacturing medical devices that aid in heart and blood vessel surgeries. Artivion competes in the Zacks Medical - Instruments industry, where it strives to innovate and expand its market presence. On February 24, 2025, Artivion reported an earnings per share (EPS) of -$0.39, missing the estimated EPS of $0.12. This was a significant deviation from the $0.11 EPS repo...

Seeking Alpha

Aug 10, 2024

Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript

Artivion, Inc. (NYSE:AORT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Suraj Kalia - Oppenheimer John McAulay - Stifel Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. And welcome to Artivion's Second Quarter 2024 Financial Conference Call.

Zacks Investment Research

Aug 8, 2024

Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates

Artivion (AORT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.06 per share a year ago.

PRNewsWire

Aug 5, 2024

Artivion to Participate in Upcoming Investor Conferences

ATLANTA , Aug. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024 at the InterContinental Boston Hotel.

PRNewsWire

Jul 25, 2024

Artivion Announces Release Date and Teleconference Call Deta...

ATLANTA , July 25, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024 financial results will be released on Thursday, August 8, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

Zacks Investment Research

May 8, 2024

Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Contin...

Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Seeking Alpha

May 6, 2024

Artivion, Inc. (AORT) Q1 2024 Earnings Call Transcript

Artivion, Inc. (NYSE:AORT ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Mike Matson - Needham & Company Suraj Kalia - Oppenheimer & Company Frank Takkinen - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. Welcome to Artivion First Quarter 2024 Financial Conference Call.

Zacks Investment Research

May 6, 2024

Artivion (AORT) Tops Q1 Earnings and Revenue Estimates

Artivion (AORT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.02 per share a year ago.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep